Native methylation sequencing for analysis of neurodegenerative conditions
- Published on: March 10 2026
Chad Pollard, CEO of Wasatch Biolabs, describes how the native sequencing capabilities of Oxford Nanopore enabled Wasatch to create new research tools with the potential to change how we understand and detect Alzheimer’s, Parkinson’s, and other neurodegenerative diseases.
